| Regional therapy [6] |
|
|
|
| Thoracic cavity delivery |
Cisplatin-fibrin |
Recruiting |
NCT01644994 |
|
Cisplatin, pemetrexed |
Recruiting |
NCT02838745 |
| Arterial delivery |
Cisplatin, gemcitabine |
Recruiting |
NCT02611037 |
| Intrapleural delivery |
Intrapleural GL-ONC1 (oncolytic virus) |
Recruiting |
NCT01766739 |
|
Intrapleural herpes simplex (HSV1716; oncolytic virus) |
Ongoing |
NCT01721018 |
|
Intrapleural mesothelin targeted (iCasp9M28z) CAR T cells |
Recruiting |
NCT02414269 |
| Immunotherapy [20] |
|
|
|
| T-cell |
Autologous tumor infiltrating lymphocytes with IL-2 |
Recruiting |
NCT02414945 |
|
Intrapleural mesothelin targeted (iCasp9M28z) CAR T cells |
Recruiting |
NCT02414269 |
|
Mesothelin targeted CIR T cells |
Ongoing |
NCT01355965 |
|
Mesothelin targeted (CART-meso) CAR T cells |
Ongoing |
NCT02159716 |
|
Mesothelin targeted CAR T cells |
Recruiting |
NCT01583686 |
|
FAP (fibroblast activation protein) targeted CAR T cells |
Recruiting |
NCT01722149 |
|
WT1 (Wilm’s tumor-1) targeted CAR T cells |
Recruiting |
NCT02408016 |
| Oncolytic virus |
Adenovirus (ONCOS 102) |
Recruiting |
NCT02879669 |
|
Intrapleural herpes simplex (HSV1716) |
Ongoing |
NCT01721018 |
|
Intrapleural vaccinia (GL-ONC1) |
Recruiting |
NCT01766739 |
|
Measles (MV-NIS) |
Recruiting |
NCT01503177 |
| Gene Transfer |
AdV-tk (sensitizes tumor to anti-viral medication) |
Ongoing |
NCT01997190 |
|
SCH 721015 (Interferon-alpha gene expressed) |
Ongoing |
NCT01119664 |
|
SCH 721015 (Interferon-alpha gene expressed) |
Ongoing |
NCT00299962 |
| Vaccine |
Multipeptide (S-588210) |
Recruiting |
NCT02661659 |
|
Modified listeria (CRS-207) |
Ongoing |
NCT01675765 |
|
Tumor cell lysate (PheraLys) on dendritic cells (MesoCancerVac) |
Recruiting |
NCT02395679 |
|
WT-1 (Wilm’s tumor-1) |
Ongoing |
NCT01265433 |
|
WT-1 (Wilm’s tumor-1) |
Ongoing |
NCT01890980 |
|
WT-1 (Wilm’s tumor-1) on dendritic cells |
Recruiting |
NCT02649829 |
| Antibody directed [23] |
|
|
|
| Anti-PD-1 |
Nivolumab |
Not yet recruiting |
NCT02497508 |
|
Nivolumab, ipilimumab |
Ongoing |
NCT02716272 |
|
Nivolumab, ipilimumab |
Not yet recruiting |
NCT02899299 |
|
Pembrolizumab |
Recruiting |
NCT02399371 |
|
Pembrolizumab |
Recruiting |
NCT02707666 |
|
Pembrolizumab |
Not yet recruiting |
NCT02784171 |
|
Pembrolizumab |
Not yet recruiting |
NCT02959463 |
| Anti-PD-L1 and anti-CTLA4 |
Atezolizumab |
Recruiting |
NCT02458638 |
|
Durvalumab |
Not yet recruiting |
NCT02899195 |
|
Durvalumab, tremelimumab |
Recruiting |
NCT02592551 |
|
Avelumab |
Recruiting |
NCT01772004 |
|
Tremelimumab |
Ongoing |
NCT01843374 |
|
Tremelimumab, durvalumab |
Recruiting |
NCT02588131 |
|
Tremelimumab, durvalumab |
Ongoing |
NCT02141347 |
| Mesothelin and growth factor receptor |
Amatuximab (mesothelin targeting antibody) |
Recruiting |
NCT02357147 |
|
Cetuximab (epidermal growth factor receptor targeting antibody) |
Recruiting |
NCT00996567 |
|
Cixutumumab (insulin-like growth factor-1 receptor targeting antibody) |
Ongoing |
NCT01160458 |
| Antibody-drug conjugates |
Anetumab (mesothelin targeted with tubulin inhibitor) |
Recruiting |
NCT02610140 |
|
GSK3052230 (fibroblast growth factor receptor targeted with Fc) |
Recruiting |
NCT01868022 |
|
LMB-100 (mesothelin targeted with immunotoxin) |
Recruiting |
NCT02798536 |
|
NGR-hTNF (tumor vessel targeted with TNFα) |
Recruiting |
NCT01358084 |
|
NGR-hTNF (tumor vessel targeted with TNFα) |
Ongoing |
NCT01098266 |
|
SS1(dsFv)PE38 (mesothelin targeted with immunotoxin) |
Ongoing |
NCT01362790 |
